RAS

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Retrieved on: 
Wednesday, March 6, 2024

Research Nester says , "The global pancreatic cancer market size is slated to expand at ~18% CAGR between 2024 and 2036.

Key Points: 
  • Research Nester says , "The global pancreatic cancer market size is slated to expand at ~18% CAGR between 2024 and 2036.
  • The American Cancer Society's estimates for pancreatic cancer in the United States for 2024 are: "About 66,440 people (34,530 men and 31,910 women) will be diagnosed with pancreatic cancer.
  • Pancreatic cancer accounts for about 3% of all cancers in the US and about 7% of all cancer deaths."
  • Biotech/oncology stocks targeting the growing global pancreatic cancer market have made headlines with recent developments and breakthroughs in treatments.

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

Retrieved on: 
Wednesday, March 6, 2024

“In RAS-mutated mCRC, we are showing the underlying mechanism through which the combination of onvansertib and bevacizumab targets the hypoxia response pathway.

Key Points: 
  • “In RAS-mutated mCRC, we are showing the underlying mechanism through which the combination of onvansertib and bevacizumab targets the hypoxia response pathway.
  • We believe this mechanism explains the strong clinical results we have seen in both our Phase 1b/2 and ONSEMBLE second-line RAS-mutated mCRC clinical trials.
  • The abstracts are available on the AACR Online Program and will be published in the online Proceedings of the AACR.
  • Following presentation, the posters will be posted to the " Scientific Presentations " section of the Cardiff Oncology website.

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Friday, March 1, 2024

“We look forward to sharing topline data from the Phase 1 portion of the Phase 1/2a trial of IMM-1-104 this month.

Key Points: 
  • “We look forward to sharing topline data from the Phase 1 portion of the Phase 1/2a trial of IMM-1-104 this month.
  • Presented preclinical data demonstrating encouraging anti-tumor activity for IMM-1-104 and IMM-6-415: In October 2023, Immuneering presented preclinical data at AACR-NCI-EORTC.
  • Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2023 were $11.9 million compared with $9.9 million for the fourth quarter of 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2023 were $4.4 million compared with $4.1 million for the same period of 2022.

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories

Retrieved on: 
Friday, March 1, 2024

Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.

Key Points: 
  • Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.
  • SAN FRANCISCO, SAN DIEGO and CASTRES, France, March 01, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc .
  • (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, and Pierre Fabre Médicament, SAS (“Pierre Fabre Laboratories”), a global player in oncology, today announced their agreement to the sale of the Company’s investigational pan-RAF inhibitor, exarafenib, and other pan-RAF program assets pursuant to the APA entered into by the parties.
  • In addition, Pierre Fabre Laboratories will assume up to $5 million of trade payables for the transferred assets.

Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress

Retrieved on: 
Monday, February 26, 2024

“2023 was a transformative year for Revolution Medicines and our pioneering RAS(ON) inhibitors.

Key Points: 
  • “2023 was a transformative year for Revolution Medicines and our pioneering RAS(ON) inhibitors.
  • Revenue: Total revenue was $0.7 million for the quarter ended December 31, 2023, compared to $15.3 million for the quarter ended December 31, 2022.
  • Net loss for the year ended December 31, 2023, included $26.9 million of operating expenses related to the wind-down of EQRx.
  • Revolution Medicines will host a webcast this afternoon, February 26, 2024, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Retrieved on: 
Wednesday, February 21, 2024

BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced the resignation of Dr. Sergio Santillana and the appointment of Dr. Caroline Germa as Chief Medical Officer. Her addition comes at a pivotal time with the Company’s focus on its clinical programs, IK-930 and IK-595, underscoring Ikena’s commitment to driving innovation in the targeted oncology space.

Key Points: 
  • Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise
    Dr. Germa will drive clinical development strategy and oversee the execution of targeted oncology programs, IK-930 and IK-595
    BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced the resignation of Dr. Sergio Santillana and the appointment of Dr. Caroline Germa as Chief Medical Officer.
  • Prior to Ikena, Dr. Germa served as the EVP, Global Medicine Development, and Chief Medical Officer at Transcenta Therapeutics, where she played a pivotal role in shaping strategic goals for the company’s oncology and non-oncology portfolio, ensuring successful execution across all clinical development functions.
  • Dr. Germa added, “I am thrilled to be joining Ikena at a time when it is primed for clinical inflection across the pipeline.
  • Dr. Santillana’s leadership was integral to bringing our programs into the clinic, and we wish him well in his future endeavors.”

Blue Star Foods Executes Transformational Master Service Agreement to Generate an Expected $20 Million Additional Revenue in 2024

Retrieved on: 
Wednesday, February 21, 2024

The fully integrated seafood provider adds value from, sourcing to preparing and distributing its gourmet meals through 2,776 retail outlets.

Key Points: 
  • The fully integrated seafood provider adds value from, sourcing to preparing and distributing its gourmet meals through 2,776 retail outlets.
  • Its products range from raw retail and food service seafood steaks and portions to dishes, such as quiche, dips, salads, and gourmet seafood entrees.
  • The Master Service Agreement calls for Blue Star to assist with sourcing, operations, and distribution of its products and to continue to serve its existing business.
  • John Keeler, CEO of Blue Star Foods, commented, “We are thrilled to join forces with this team in what is truly a transformational event for Blue Star Foods.

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Retrieved on: 
Tuesday, February 20, 2024

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for its lead clinical-stage program, IMM-1-104, for the treatment of patients with pancreatic ductal adenocarcinoma (PDAC) who have failed one line of treatment. IMM-1-104 is designed to provide universal-RAS activity through deep cyclic inhibition of the MAPK pathway with once-daily oral dosing.

Key Points: 
  • IMM-1-104 is designed to provide universal-RAS activity through deep cyclic inhibition of the MAPK pathway with once-daily oral dosing.
  • “We welcome FDA’s decision to grant Fast Track designation for IMM-1-104.
  • Our Phase 1/2a study is designed to evaluate IMM-1-104 in pancreatic cancer, as well as a number of other tumor types associated with the RAS pathway.
  • City of Hope offers many clinical trials testing innovative treatments for people with pancreatic cancer," Chung said.

JEDEC® Publishes GDDR7 Graphics Memory Standard

Retrieved on: 
Tuesday, March 5, 2024

This groundbreaking new memory standard is available for free download from the JEDEC website .

Key Points: 
  • This groundbreaking new memory standard is available for free download from the JEDEC website .
  • JESD239 GDDR7 offers double the bandwidth over GDDR6, reaching up to 192 GB/s per device, and is poised to meet the escalating demand for more memory bandwidth in graphics, gaming, compute, networking and AI applications.
  • JESD239 GDDR7 is the first JEDEC standard DRAM to use the Pulse Amplitude Modulation (PAM) interface for high frequency operations.
  • “The groundbreaking GDDR7 memory standard unveiled today represents a pivotal step towards unlocking the potential of next-generation consumer, gaming, commercial, and enterprise devices,” said Joe Macri, Compute and Graphics CTO and Corporate Fellow at AMD.

Tachyum Demonstrates PMU Running on Prodigy FPGA Emulation System

Retrieved on: 
Tuesday, February 20, 2024

Tachyum ® today announced that it has added a Performance Monitoring Unit (PMU) to its Prodigy® FPGA emulation system, empowering customers and partners with the ability to address bottlenecks and better optimize Prodigy performance for all applications and workloads.

Key Points: 
  • Tachyum ® today announced that it has added a Performance Monitoring Unit (PMU) to its Prodigy® FPGA emulation system, empowering customers and partners with the ability to address bottlenecks and better optimize Prodigy performance for all applications and workloads.
  • The PMU is an essential tool for collecting information about performance bottlenecks.
  • It offers the ability to record a wide range of events that encompass every aspect of the Prodigy Universal Processor without slowing down the application itself.
  • The PMU’s wide range of performance counters – supported by both software C-model and FPGA – facilitates both system debugging and performance tuning.